CLAIMS

1. A substantially pure, isolated or recombinant polypeptide which:

a) comprises or consists of the amino acid sequence shown in figure 2b, SEQ ID NO: 2;

b) is a derivative having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence shown in figure 2b, SEQ ID NO: 2; or

c) is a fragment of a polypeptide as defined in a) or b) above, which is at least ten amino acids long;

wherein the recombinant polypeptide comprises amino acids 73-86 of SEQ ID NO.: 2.

2. A polypeptide as claimed in claim 1 which is provided as part of a fusion polypeptide.

3. A polypeptide as claimed in claim 2 wherein the fusion polypeptide comprises Green Fluorescent Protein or the DsRed Fluorescent Protein.

4. An isolated or recombinant nucleic acid molecule which:

a) comprises or consists of the DNA sequence shown in Figure 2a or its RNA equivalent;

b) a sequence which is complementary to the sequences of a);

c) a sequence which codes for the same or polypeptide, as the sequences of a) or b);

d) a sequence which shows substantial identity with any of those of a), b) and c); or

e) a sequence which codes for a derivative or fragment of an amino acid molecule shown in Figure 1;

wherein the nucleic acid molecule comprises a nucleic acid sequence encoding amino acids 73-86 of SEQ ID NO.: 2.

5 A vector comprising one or more nucleic acid molecules as defined in claim 4.

6. A host cell transformed/transfected with a vector as defined in claim 5.

7. A substantially pure, isolated or recombinant polypeptide which:

a) comprises or consists of the amino acid sequence shown in figure 3b (SEQ ID NO.: 4);

b) is a derivative having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence shown in figure 3b; or

c) is a fragment of a polypeptide as defined in a) or b) above, which is at least ten amino acids long;

wherein the polypeptide comprises amino acids 194 to 203 of SEQ ID NO.: 4.

8 A polypeptide as claimed in claim 7 which is provided as part of a fusion polypeptide.

9. A polypeptide as claimed in claim 8 wherein the fusion polypeptide comprises Green Fluorescent Protein or the DsRed Fluorescent Protein.

10. An isolated or recombinant nucleic acid molecule which:

a) comprises or consists of the DNA sequence shown in Figure 3a (SEQ ID NO.: 3) or its RNA equivalent;

b) a sequence which is complementary to the sequences of a);

c) a sequence which codes for the same or polypeptide, as the sequences of a) or b);

f) a sequence which shows substantial identity with any of those of a), b) and c); or

g) a sequence which codes for a derivative or fragment of an amino acid molecule shown in Figure 1;

wherein the nucleic acid comprises a nucleic acid sequence encoding amino acids 194 to 203 of SEQ ID NO.: 4.

11 A vector comprising one or more nucleic acid molecules as defined in claim 10.

12. A host cell transformed/transfected with a vector as defined in claim 11.

13. A method of screening for and/or diagnosis of a neurological or neuropsychiatric condition in a subject, which method comprises the step of detecting and/or quantifying the amount of a polypeptide in a biological sample obtained from said subject, wherein the polypeptide is selected from:

a) the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO.: 4);

b) a derivative having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO.: 4); and

c) a fragment of a polypeptide as defined in a) or b) above, which is at least ten amino acids long.

14. A method as claimed in claim 13, wherein the polypeptide is provided as part of a fusion polypeptide.

15. A method as claimed in claim 14, wherein the fusion polypeptide is selected from the group consisting of Green Fluorescent Protein and DsRed Fluorescent Protein.

16. A method for the prophylaxis and/or treatment of a neurological or neuropsychiatric condition in a subject, which comprises administering to said subject a therapeutically effective amount of at least one polypeptide , wherein the polypeptide is selected from:

a) the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO.: 4);

b) a derivative having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO.: 4); and

c) a fragment of a polypeptide as defined in a) or b) above, which is at least ten amino acids long.

17. A method of screening for and/or diagnosis of a neurological or neuropsychiatric condition in a subject, which method comprises the step of detecting and/or quantifying the amount of a nucleic acid in a biological sample obtained from said subject, wherein the nucleic acid molecule:

a) comprises the DNA sequence shown in Figure 2a or 3a (SEQ ID NO.: 1 or SEQ ID NO.: 3), or its RNA equivalent;

b) has a sequence which is complementary to the sequences of a);

c) has a sequence which codes for the same polypeptide as the sequences of a) or b);

d) has a sequence which shows substantial identity with any of those of a), b) and c); or

e) has a sequence which codes for a derivative or fragment of an amino acid molecule shown in Figure 2a or 3a (SEQ ID NO.: 1 or SEQ ID NO.: 3).

18. A method for the prophylaxis and/or treatment of a neurological or neuropsychiatric condition in a subject, which comprises administering to said subject a therapeutically effective amount of at least one nucleic acid as defined in claim 17.

19. An antibody, which binds to a polypeptide as defined in claims 1 or 7, or to a fragment of such a polypeptide.

20. An antibody as claimed in claim 19, which binds specifically to a polypeptide as defined in claims 1 or 7.

21. An antibody as claimed in claim 19 or claim 20, which is conjugated to a therapeutic moiety.

22. An antibody as claimed in claim 21 wherein the therapeutic moiety is selected from a second antibody or a fragment or derivative thereof, a cytotoxic agent or a cytokine.

23. A method for the prophylaxis and/or treatment of a neurological or neuropsychiatric condition in a subject, which comprises administering to said subject a therapeutically effective amount of an antibody, as defined in claims 19-22, which binds to at least one polypeptide, wherein the polypeptide is selected from:

a) the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO.: 4);

b) a derivative having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO.: 4); and

c) a fragment of a polypeptide as defined in a) or b) above, which is at least ten amino acids long.

24. A pharmaceutical formulation comprising at least one polypeptide, wherein the polypeptide is selected from:

a) the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO.: 4);

b) a derivative having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO.: 4); and

c) a fragment of a polypeptide as defined in a) or b) above, which is at least ten amino acids long;

at least one nucleic acid molecule wherein the nucleic acid molecule:

a) comprises the DNA sequence shown in Figure 2a or 3a (SEQ ID NO.: 1 or SEQ ID NO.: 3), or its RNA equivalent;

b) has a sequence which is complementary to the sequences of a);

c) has a sequence which codes for the same polypeptide as the sequences of a) or b);

d) has a sequence which shows substantial identity with any of those of a), b) and c); or

e) has a sequence which codes for a derivative or fragment of an amino acid molecule shown in Figure 2a or 3a (SEQ ID NO.: 1 or SEQ ID NO.: 3);

or at least one antibody that binds to said polypeptide, optionally together with one or more pharmaceutically acceptable excipients, carriers or diluents.

25. A pharmaceutical formulation as claimed in claim 24, wherein the pharmaceutical formulation is a vaccine.

26. A pharmaceutical formulation as claimed in claim 25, which comprises one or more suitable adjuvants.

27. A method for the prophylaxis and/or treatment of a neurological or neuropsychiatric condition in a subject, which comprises administering to said subject a therapeutically effective amount of at least one polypeptide, wherein the polypeptide is selected from:

a) the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO.: 4);

b) a derivative having one or more amino acid substitutions, deletions or insertions relative to the amino acid sequence shown in figures 2b or 3b (SEQ ID NO: 2 or SEQ ID NO.: 4); and

c) a fragment of a polypeptide as defined in a) or b) above, which is at least ten amino acids long;

at least one nucleic acid molecule wherein the nucleic acid molecule:

a) comprises the DNA sequence shown in Figure 2a or 3a (SEQ ID NO.: 1 or SEQ ID NO.: 3), or its RNA equivalent;

b) has a sequence which is complementary to the sequences of a);

c) has a sequence which codes for the same polypeptide as the sequences of a) or b);

d) has a sequence which shows substantial identity with any of those of a), b) and c); or

e) has a sequence which codes for a derivative or fragment of an amino acid molecule shown in Figure 2a or 3a (SEQ ID NO.: 1 or SEQ ID NO.: 3);

or at least one antibody that binds to said polypeptide.

28. A method of screening for compounds that modulate the expression of a polypeptide as defined in claims 1 or 7, which comprises the step of determining the presence or absence and/or quantifying at least one polypeptide as defined in claims 1 or 7 or at least one antibody as defined in claim 19 or claim 20 in a biological sample.

29. A method for monitoring/assessing a neurological or neuropsychiatric condition treatment in a patient, which comprises the step of determining the presence or absence and/or quantifying at least one polypeptide as defined in claims 1 or 7 or at least one antibody as defined in claim 19 or claim 20 in a biological sample obtained from said patient.